🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareFDA compounding enforcement update — June 2026 guidance document Page 9

FDA compounding enforcement update — June 2026 guidance document

RegAffairsDC Mon, Feb 26, 2024 at 4:00 PM 336 replies 53,782 viewsPage 9 of 20
KristenIndy
Member
623
2,678
May 2024
Indianapolis, IN
Mar 9, 2024 at 11:14 PM#41
hank_denver said:
Keep the original post as written when you update it, and add the correction underneath.

That reframing is the part I needed. Adding it to my notes with a link back to this thread.

23 23LondonLisa, mike_nyc, VendorMark and 20 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Mar 10, 2024 at 8:30 AM#42

Adding the clinical framing, because it changes how the question reads. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

22 22PharmD_Rodriguez, julia.endo, JessicaM_2024 and 19 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Mar 10, 2024 at 5:46 PM#43

Moderator note: the sourcing question belongs in the vendor section and has been split out. Carry on.

Last edited: Mar 10, 2024 at 7:46 PM
21 21DoseLogDan, SleepFixSam, PurityPaulOR and 18 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
ben_calgary
Member
245
1,123
Oct 2024
Calgary, CA
Mar 11, 2024 at 3:02 AM#44
LibrarianMeg said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

There is a second half to this that has not been said yet. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

Last edited: Mar 11, 2024 at 9:02 AM
20 20JakeSmashed95, NauseaFreeNow, SteveThurs and 17 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Mar 11, 2024 at 12:18 PM#45

Adding the numbers, since they settle part of this. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

19 19ChrisMacros, KetoKyle, CanadaChris and 16 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register